 |
 |  |
        |
 Press Release: February 1, 2010 Romark Laboratories announced that it has initiated enrollment of patients in a clinical trial of Alinia® (nitazoxanide) for treating acute uncomplicated influenza including illness caused by the currently circulating H1N1 strain. Study Showing Improved Virologic Response with Nitazoxanide in Chronic Hepatitis C Published in Gastroenterology Press Release: March 02, 2009 A study evaluating nitazoxanide in combination with peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C virus (HCV) infection with genotype 4 was published in the March issue of Gastroenterology, the official journal of the American Gastroenterological Association Institute (AGA Institute). Romark and Chugai Pharmaceutical Enter into Exclusive Licensing Agreement for Nitazoxanide in Japan Press Release: February 17, 2009 Romark Laboratories, a privately held biopharmaceutical company, and Chugai Pharmaceutical Co. Ltd., a member of the Roche Group, today announced that the two companies have entered into an exclusive license agreement for the development and commercialization of nitazoxanide as a treatment of chronic hepatitis C in Japan. Romark Announces Presentation of New Data for Controlled Release Nitazoxanide in Chronic Hepatitis C Press Release: February 17, 2009 Romark Laboratories, a privately held biopharmaceutical company, today announced results from international Phase I and II clinical trials evaluating a controlled release version of nitazoxanide in the treatment of chronic hepatitis C virus (HCV) infection. In the phase II study in treatment-naïve patients infected with HCV genotype 4, 82% (n=17) and 100% (n=16) of patients receiving low and high doses of controlled release nitazoxanide, respectively, experienced undetectable serum HCV RNA (<12 IU/mL) after 12 weeks of combination therapy with peginterferon and ribavirin. Romark Announces Presentation of New Data For Nitazoxanide in Chronic Hepatitis C at AASLD 2008 Press Release: November 3, 2008 Romark Laboratories, a privately held biopharmaceutical company, today announced that data from studies of nitazoxanide in chronic hepatitis C virus (HCV) infection are being communicated in three presentations made at the 59th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), also known as The Liver Meeting®, and the 50th Anniversary Meeting of the International Association for the Study of the Liver (IASL) in San Francisco, October 31 - November 4, 2008. Romark Announces Presentation of New Data For Nitazoxanide in Chronic Hepatitis C at EASL 2008 Press Release: April 23, 2008 Romark Laboratories, a privately held biopharmaceutical company, today announced that data from studies of nitazoxanide in chronic hepatitis C virus (HCV) infection are being communicated in four presentations made at the 43rd Annual Meeting of the European Association for the Study of the Liver (EASL), held in Milan, Italy this week. Romark Laboratories Initiates Phase II Study Of Nitazoxanide In Treatment-Naïve Patients With Chronic Hepatitis C Genotype 1 Press Release: April 18, 2008 Romark Laboratories, a privately held biopharmaceutical company, today announced that it has begun enrolling patients in a U.S. clinical trial to evaluate nitazoxanide for the treatment of chronic hepatitis C. Romark Laboratories Names Emmet B. Keeffe, M.D. Vice President and Chief Medical Officer Press Release: January 7, 2008 Romark Laboratories, L.C., a privately-owned biotechnology company, today announced that Emmet B. Keeffe, M.D., M.A.C.P., has joined the Company as Vice President and Chief Medical Officer. Romark Laboratories Raises $18 Million in Institutional Financing Press Release: December 21, 2007 Romark Laboratories, L.C., a privately-owned biotechnology company, today announced the closing of an $18 million institutional financing with the D.E. Shaw Group. Phase II Study Shows that Nitazoxanide Significantly Improves Response to Standard of Care in Patients with Chronic Hepatitis C Press Release: November 2, 2007 Romark Laboratories, a privately-owned biotechnology company, today announced results of a randomized phase II clinical trial showing that 79% of interferon-naïve patients with chronic hepatitis C genotype 4 receiving nitazoxanide plus the standard of care had a sustained virologic response (SVR), or undetectable level of virus, 12 weeks following treatment, compared to 43% of patients receiving the standard of care without nitazoxanide. Romark Initiates Clinical Trial of Alinia® for Chronic Hepatitis C in the United States Press Release: August 15, 2007 Romark Laboratories announced that it has initiated a phase II clinical trial of Alinia® (nitazoxanide) for treating chronic hepatitis C in the United States. Romark Completes Financing with D. E. Shaw Group Press Release: May 14, 2007 Romark Laboratories announced that it has completed a $27 million financing with Laminar Direct Capital, a member of the D. E. Shaw Group. The financing was structured as a sale of senior secured notes and equity units. Merrill Lynch acted as placement agent for the transaction. |
 |
 |
||